Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Biological Activity, and PK of ND-L02-s0201 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
NCT03538301 is registered in ClinicalTrials.gov with Nitto Denko Corporation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Biological Activity, and PK of ND-L02-s0201 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
- Lead sponsor
- Nitto Denko Corporation
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- June 18, 2018
- Completion date
- August 24, 2022
- Enrollment
- 123 (actual)
- Sites
- 33
Conditions
As the registry lists them; a condition with its own page is linked.